Anupam Rasayan India Limited

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Anupam Rasayan to acquire up to 48.2% stake in Bliss GVS Pharma as #ANURAS expands pharma value-chain bet

Anupam Rasayan is moving beyond chemistry into formulations. Can the Bliss GVS Pharma deal justify the market’s high expectations?

bySrinath

May 23, 2026

Anupam Rasayan (NSE: ANURAS) set to acquire Jayhawk Fine Chemicals for $150m

Anupam Rasayan India acquires Jayhawk Fine Chemicals for $150M, expanding its global specialty chemicals footprint. Find out how this deal is reshaping the sector.

byVenkatesh

December 10, 2025

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Anupam Rasayan to acquire up to 48.2% stake in Bliss GVS Pharma as #ANURAS expands pharma value-chain bet

Anupam Rasayan (NSE: ANURAS) set to acquire Jayhawk Fine Chemicals for $150m

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?